At a glance
ClinicalIndex Comparison RecordN/ACompleted· 446 enrolled
Drug / intervention
REVEAL Implantable Cardiac Monitordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
REVEAL AF: Incidence of AF in High Risk Patients
In Brief
A clinical study evaluating REVEAL Implantable Cardiac Monitor for Atrial Fibrillation. Completed, enrolled 446 participants across 58 sites in 7 countries.
Detailed Summary
This study is to determine, through continuous monitoring with the Reveal implantable cardiac monitor (ICM), the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for having AF and to understand how physicians manage these patients after AF has been detected. This study will also seek to identify what patient characteristics are most predictive of developing AF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesAustria, Germany, Italy, Netherlands, Slovenia, Spain, United States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionJan 2017
Study CompletionJan 2017
TodayJul 2026
First PostedNov 15, 2012
Enrollment StartNov 13, 2012
Primary CompletionJan 13, 2017
Study CompletionJan 30, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.6 years ago
Interventions
REVEAL Implantable Cardiac Monitordevice